Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Articles
Practice Management
Communication Strategies Must Be Tailored to a Medication’s Targeted Population: Lessons from the Case of BiDil
Stakeholder Perspective
Much More than Biomarkers: Sociodemographic Variables in Personalized Medicine
Read More
Practice Management
Yet Another Blow to the Medicaid Expansion
Read More
Original Research
New Drug Therapies for the Treatment of Overweight and Obese Patients
Stakeholder Perspective
The Modern Epidemic of Obesity
Read More
Introduction
Cardiometabolic Risk Factors: Novel Approaches Can Improve Patient Outcomes
Read More
Practice Management
Assessing Medicare Beneficiary Eligibility for Medication Therapy Management Programs Using PINNACLE, a National Cardiovascular Data Registry
Stakeholder Perspective
Hanging Together for Patient-Centered Medical Care
Read More
FDA Approvals
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Read More
FDA Approvals
Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations
Read More
New Directions in the Treatment of Multiple Myeloma: Reports on Carfilzomib Therapy from ASCO 2013 and EHA 2013
Read More
Practice Management
FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials
Read More
Lung Cancer
,
Oncology
Crizotinib Superior to Standard Chemotherapy in ALK-Positive Lung Cancer
Read More
168
169
170
171
172
173
174
Page 171 of 244
Results 1701 - 1710 of 2434